ReviewCost effectiveness and resource allocation : C/E2022

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review.

Ghader Mohammadnezhad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.